| Gastric Cancer Management and Outcomes | Lifetime | 69 | KR 5 | 99.74 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 49 | KR 6 | 99.59 |
| Metastasis and carcinoma case studies | Lifetime | 54 | KR 7 | 99.18 |
| Renal cell carcinoma treatment | Lifetime | 135 | KR 2 | 99.21 |
| Colorectal Cancer Treatments and Studies | Lifetime | 186 | KR 8 | 99.34 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 264 | KR 22 | 98.79 |
| Cancer Genomics and Diagnostics | Lifetime | 700 | KR 9 | 98.75 |
| Renal and related cancers | Lifetime | 363 | KR 3 | 98.20 |
| HER2/EGFR in Cancer Research | Lifetime | 362 | KR 10 | 98.41 |
| Peptidase Inhibition and Analysis | Lifetime | 747 | KR 10 | 97.59 |
| Cancer Treatment and Pharmacology | Lifetime | 942 | KR 12 | 97.50 |
| Esophageal Cancer Research and Treatment | Lifetime | 647 | KR 11 | 96.80 |
| Multiple and Secondary Primary Cancers | Lifetime | 417 | KR 10 | 95.98 |
| Cancer survivorship and care | Lifetime | 630 | KR 6 | 96.45 |
| Vascular Tumors and Angiosarcomas | Lifetime | 297 | KR 2 | 96.23 |
| Fibroblast Growth Factor Research | Lifetime | 536 | KR 4 | 93.60 |
| Telomeres, Telomerase, and Senescence | Lifetime | 635 | KR 9 | 91.43 |
| Cancer-related cognitive impairment studies | Lifetime | 691 | KR 13 | 87.87 |
| Soft tissue tumors and treatment | Lifetime | 867 | KR 23 | 65.79 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 9 | KR 2 | 99.86 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 3 | KR 2 | 99.83 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 20 | KR 1 | 99.31 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 52 | KR 3 | 99.12 |
| Renal cell carcinoma treatment | 2021-2025 | 76 | KR 3 | 98.65 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 297 | KR 9 | 98.85 |
| Cancer Genomics and Diagnostics | 2021-2025 | 238 | KR 5 | 98.18 |
| HER2/EGFR in Cancer Research | 2021-2025 | 79 | KR 6 | 98.72 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 230 | KR 5 | 95.83 |
| Fibroblast Growth Factor Research | 2021-2025 | 32 | KR 2 | 93.83 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 516 | KR 31 | 96.19 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 619 | KR 21 | 96.15 |
| Peptidase Inhibition and Analysis | 2021-2025 | 332 | KR 7 | 93.44 |
| Metastasis and carcinoma case studies | 2021-2025 | 152 | KR 26 | 93.20 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 943 | KR 24 | 90.19 |
| Cancer survivorship and care | 2021-2025 | 900 | KR 21 | 87.37 |
| Renal and related cancers | 2021-2025 | 669 | KR 14 | 84.92 |
